Antisense Inhibitors of ApoC3 and Lp(a) Show Positive Results in Phase 1 and 2 Studies
In a Phase 2 trial, patients with very high to
August 5, 2015
In a Phase 2 trial, patients with very high to
Which of the many so called “risk factors” correlated with
Sign up to receive updates on educational opportunities, complimentary content, exclusive discounts, and more.
Cardiometabolic Health Congress
1801 N Military Trail, Ste 110
Boca Raton, FL, 33431
Copyright © 2023, Cardiometabolic Health Congress. All Rights Reserved.
Sign up to receive updates on educational opportunities, complimentary content, exclusive discounts, and more.
